Skip to main content
CSPC Pharmaceutical Group Limited logo

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,520 across all filing types
Latest filing 2023-03-16 Regulatory Filings
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
INSIDE INFORMATION - PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE YEAR ENDED 31 DECEMBER 2022
Regulatory Filings Classification · 95% confidence The document is an announcement by CSPC Pharmaceutical Group Limited regarding the principal financial information of its subsidiary CSPC Innovation Pharmaceutical Co., Ltd. for the year ended 31 December 2022. It references the subsidiary's 2022 Annual Report published on the Shenzhen Stock Exchange website and provides extracted financial data and accounting indicators from that report. The document is titled as an announcement and includes financial highlights but does not contain the full annual report itself. It is a disclosure of key financial information rather than the complete official annual report. The document length is 7272 characters, which is relatively short for a full annual report but consistent with an announcement summarizing principal financial data. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is an announcement of financial information extracted from the annual report, not the full annual report itself.
2023-03-16 English
VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTANCE OF APPLICATION FOR MARKETING APPROVAL OF ENLONSTOBART FOR INJECTION
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding the acceptance of an application for marketing approval of a pharmaceutical product by the National Medical Products Administration (NMPA) of China. It is a short announcement (2265 characters) and does not contain financial data, detailed financial performance, or regulatory certifications. It is not a report, transcript, or detailed presentation but an update on a regulatory approval process related to the company's product. This fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2023-03-10 English
DATE OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is a short announcement from CSPC Pharmaceutical Group Limited stating the date of a board meeting to approve the annual results for the year ended 31 December 2022 and to consider the payment of a final dividend. It does not contain any financial data or detailed report content but merely announces the upcoming board meeting and its agenda. The document length is only 1318 characters, which is quite short and fits the pattern of an announcement rather than a full report. According to the rules, such announcements about board meetings to approve results and dividends are best classified as Regulatory Filings (RNS) because they do not contain the actual report or financial statements but are regulatory announcements related to corporate governance and reporting schedules.
2023-03-10 English
VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN PHASE III CLINICAL TRIAL OF DUOENDA (MITOXANTRONE HYDROCHLORIDE LIPOSOME INJECTION) FOR THE TREATMENT OF RECURRENT METASTATIC NASOPHARYNGEAL CARCINOMA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding the dosing of the first patient in a Phase III clinical trial for a new drug. It is an announcement of a clinical trial milestone and does not contain financial data, regulatory certifications, or detailed financial reports. The document is relatively short (3375 characters) and serves as a news update rather than a formal financial or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is not related to shareholder meetings, voting results, or capital changes. The content is best classified as a general regulatory announcement or company update that does not fit other specific categories, thus falling under Regulatory Filings (RNS).
2023-03-02 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 28 FEBRUARY 2023
Regulatory Filings Classification · 95% confidence The document is a monthly return report detailing movements in issued shares, share options, and other share capital information for CSPC Pharmaceutical Group Limited. It is addressed to the Hong Kong Exchanges and Clearing Limited and follows a specific form (FF301) related to securities movements under the Exchange Listing Rules. The content focuses on share capital changes, share options, and confirmations related to securities, without any financial performance data, earnings, or management commentary. It is not an annual or interim report, earnings release, or investor presentation. The document is a regulatory submission reporting share capital movements and related confirmations, which fits the category of Regulatory Filings (RNS) as a general regulatory announcement that does not fit into more specific categories like Share Issue/Capital Change (SHA) because it is a routine monthly return rather than a specific capital change event.
2023-03-01 English
REMUNERATION COMMITTEE - TERMS OF REFERENCE
Remuneration Information Classification · 95% confidence The document is titled 'REMUNERATION COMMITTEE – TERMS OF REFERENCE' and details the composition, meetings, responsibilities, reporting, and authority of the remuneration committee of CSPC Pharmaceutical Group Company. It focuses on the committee's role in setting and reviewing remuneration policies for directors and senior management. There is no financial data, audit information, or report publication mentioned. The content aligns with detailed compensation governance and committee responsibilities, which fits the definition of a Remuneration Information report. The document length is 4102 characters, which is sufficient for a detailed committee terms of reference document. Therefore, the appropriate classification is Remuneration Information (DEF 14A).
2023-02-23 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.